WP3: Glycoconjugation

WP3 Glycoconjugation: while most of the classic conjugation approaches are based on targeting the abundant lysines and glutamates exposed on the protein surface, typically leading to random conjugation, GSK has recently contributed to the development of new selective conjugation methods, directed at the modification of tyrosine residues or disulfide bridges or of protein with engineered and exposed cysteines. The crystal structure of exotoxin A from PA is available and can be used as starting point for the design of selective conjugation approaches.